Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.
Humans
Neuromyelitis Optica
/ cerebrospinal fluid
Aquaporin 4
/ immunology
Male
Female
Middle Aged
Adult
Myelin-Oligodendrocyte Glycoprotein
/ immunology
Complement Activation
Immunoglobulin G
/ cerebrospinal fluid
Autoantibodies
/ cerebrospinal fluid
Aged
Complement C5a
/ cerebrospinal fluid
Young Adult
Multiple Sclerosis
/ cerebrospinal fluid
Complement C3a
/ metabolism
Complement Membrane Attack Complex
/ metabolism
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
medline:
12
8
2024
pubmed:
12
8
2024
entrez:
12
8
2024
Statut:
ppublish
Résumé
In myelin oligodendrocyte glycoprotein IgG-associated disease (MOGAD) and aquaporin-4 IgG+ neuromyelitis optica spectrum disorder (AQP4+NMOSD), the autoantibodies are mainly composed of IgG1, and complement-dependent cytotoxicity is a primary pathomechanism in AQP4+NMOSD. We aimed to evaluate the CSF complement activation in MOGAD. CSF-C3a, CSF-C4a, CSF-C5a, and CSF-C5b-9 levels during the acute phase before treatment in patients with MOGAD (n = 12), AQP4+NMOSD (n = 11), multiple sclerosis (MS) (n = 5), and noninflammatory neurologic disease (n = 2) were measured. CSF-C3a and CSF-C5a levels were significantly higher in MOGAD (mean ± SD, 5,629 ± 1,079 pg/mL and 2,930 ± 435.8 pg/mL) and AQP4+NMOSD (6,017 ± 3,937 pg/mL and 2,544 ± 1,231 pg/mL) than in MS (1,507 ± 1,286 pg/mL and 193.8 ± 0.53 pg/mL). CSF-C3a, CSF-C4a, and CSF-C5a did not differ between MOGAD and AQP4+NMOSD while CSF-C5b-9 (membrane attack complex, MAC) levels were significantly lower in MOGAD (17.4 ± 27.9 ng/mL) than in AQP4+NMOSD (62.5 ± 45.1 ng/mL, The complement pathway is activated in both MOGAD and AQP4+NMOSD, but MAC formation is lower in MOGAD, particularly in those with mild attacks, than in AQP4+NMOSD. These findings may have pathogenetic and therapeutic implications in MOGAD.
Identifiants
pubmed: 39133885
doi: 10.1212/NXI.0000000000200293
doi:
Substances chimiques
Aquaporin 4
0
Myelin-Oligodendrocyte Glycoprotein
0
AQP4 protein, human
0
Immunoglobulin G
0
Autoantibodies
0
Complement C5a
80295-54-1
Complement C3a
80295-42-7
Complement Membrane Attack Complex
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM